key: cord-0742305-tzkv5h0e
authors: Juárez Guerrero, Alba; Dominguez Estirado, Alicia; Crespo Quirós, Jimena; Rojas-Pérez Ezquerra, Patricia
title: Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19
date: 2021-07-19
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.07.012
sha: 7155c68edfb4b71ef4ed2c2ba7afcb693ae3a841
doc_id: 742305
cord_uid: tzkv5h0e

nan

Vaccination is an effective intervention to prevent Coronavirus Disease 2019 There were no major differences in hypersensitivity-related side-effects versus placebo 27 with either vaccine during clinical trials; they were observed in 0.63% of Pfizer-28 BioNTech and 1.5% of Moderna vaccine clinical trial participants who received the 29 vaccine compared to 0.51% and 1.1%, respectively, in the placebo groups [1, 2] . Both Rangsdorf, Germany) with readings at day 2 (D2) and day 4 (D4). The study protocols 47 our hospital.

The study population was comprised of 26 patients (Table 1) Only one patient did not receive two doses whereas 96% received both.

Therefore, these reactions were mild, self-limiting, and did not preclude a second vaccine 

In this series, most reactions occurred after the first dose, however, these data could be 110 prejudiced by the fact that patients would probably consult physicians more frequently 111 after a first dose reaction rather than a second dose reaction.

These data indicate that DLLR and mild exanthemas are not a contraindication for a 113 second mRNA vaccination. 

Safety and 117 Efficacy of the BNT162b2 mRNA COVID-19 Vaccine